Navigation Links
Aware, Inc. Amends and Extends Dutch Auction Tender Offer
Date:4/20/2009

BEDFORD, Mass., April 3 /PRNewswire-FirstCall/ -- Aware, Inc. (Nasdaq: AWRE) today announced that it has amended and extended its modified Dutch Auction tender offer. As a result of comments and a request from the Securities and Exchange Commission (the "SEC"), Aware has agreed to narrow the price range of the tender offer to between $2.20 and $2.60 per share. Originally, the minimum purchase price was $1.80 per share. Aware has also extended the expiration date for the tender offer to 5 p.m., New York City time, on Friday, April 17, 2009.

The terms of the tender offer are set forth in Aware's Offer to Purchase, dated March 5, 2009 (as amended on March 31, 2009, and as supplemented by the Supplement to the Offer to Purchase (the "Supplement") dated April 3, 2009, the "Offer to Purchase"), the related letter of transmittal (as it may be amended or supplemented from time to time, the "Letter of Transmittal"), and the Tender Offer Statement on Schedule TO, including Amendment No. 1 and Amendment No. 2 (the "Schedule TO"), filed with the SEC in connection with the tender offer. The Offer to Purchase, the Letter of Transmittal, and the Supplement constitute the "tender offer".

Under the terms of the tender offer, stockholders will have the opportunity to tender some or all of their shares at a price not greater than $2.60 nor less than $2.20 per share. Based on the number of shares tendered and the prices specified by the tendering stockholders, Aware will determine the lowest price per share within the range that will enable it to purchase up to 3,500,000 shares, or such lesser number of shares as are properly tendered. Aware also reserves the right in the tender offer to purchase up to an additional 2% of its shares outstanding. All shares purchased in the tender offer will be purchased at the same determined price per share regardle
'/>"/>

SOURCE Aware, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology news :

1. Aware, Inc. Introduces Biometrics Software for Tenprint Autocapture
2. Aware, Inc. Announces Richard Moberg to Return as CFO
3. Aware, Inc. Reports Fourth Quarter and 2007 Financial Results
4. Sun Microsystems and Aware, Inc. Announce Integration of Awares BioSP with Sun Identity Management Solutions
5. Aware, Inc. Reports Fourth Quarter and 2008 Financial Results
6. Aware, Inc. Commences Dutch Auction Tender Offer
7. Aware, Inc. Commences Dutch Auction Tender Offer
8. Aware, Inc. Amends and Extends Dutch Auction Tender Offer
9. Aware, Inc. Announces Preliminary Results of Dutch Auction Tender Offer
10. Thinking makes it so: Science extends reach of prosthetic arms
11. Successful cooperation extends Dragon Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2015)... Calif. , Aug. 5, 2015 The ... continuous growth in applications, penetration into newer sectors, and ... year. The global biosensors space has seen the entry ... the market so far. (Photo - ... & Sullivan, Analysis of the Global Biosensors Market ...
(Date:8/3/2015)... 3, 2015 Synaptics, Inc. (Nasdaq: SYNA ... announced that members of the executive management team will ... Global Technology Leadership Forum on Tuesday, August 11, 2015 ... held at the Sonnenalp Resort in Vail, ... include forward-looking information. An audio webcast of the event ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julho de 2015 ... Genômica (ICG-10, www.icg-10.org ) será realizada pela BGI de ... China . A conferência está ... inauguração em 2006, a ICG se tornou uma das ... e um dos encontros científicos mais dinâmicos, entusiastas e ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... Office has granted an exclusive license of a novel ... Inc., which plans to initiate early-stage human clinical trials ... Gary Landreth, PhD, the Riuko and Archie G. Co ... PhD, co-founded ReXceptor after discovering that bexarotene (a medication ...
... and Oxford, UK Cancer cells are a problem for ... blithely metastasize to set up shop in places where they ... this way is a tumor suppressor named p53. This protein ... those that are damaged beyond repair. Not surprisingly, p53,s critical ...
... across the UK has shown a grass hybrid species ... The BBSRC-funded scientists, from Rothamsted Research, the James Hutton ... at Aberystwyth University, Lancaster University and the University of ... perennial ryegrass ( Lolium perenne ) with a closely ...
Cached Biology News:Research spinoff ReXceptor gets license for Alzheimer's treatment 2Reviving a foe of cancer 2New grass hybrid could help reduce the likelihood of flooding 2
(Date:8/28/2015)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: ... the development of autologous cell therapies, today reported ... 2015, corporate highlights, and near-term milestones.  The company,s ... www.sedar.com ,  www.edgar.com and at ... to launch its RCS-01 treatment for aging and ...
(Date:8/28/2015)... ... ... Since the initial launch of FireflySci Inc. (FFS) in early 2015, the company continues to ... such as the Fonz in a lab coat and Large Marge have been posted on ... , FireflySci is proud to be the only cuvette manufacturer is the world ...
(Date:8/27/2015)... ... ... Capital Edge Consulting , a nationwide consulting firm that specializes in helping ... one of the top 5000 companies listed on the 2015 Inc. 5000 , ... is truly an honor to be recognized as one of America’s fastest growing companies. ...
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - Portage Biotech ... PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), ... Phase I study of BHV-0223, a glutamate modulating ... regarding BHV-0223 and recently obtained clearance from the ... with human testing. Portage holds 54% equity interest ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4
... , , , , ... Imagenetix, Inc. (OTC Bulletin Board: IAGX) announced today results for its first fiscal ... from the $1,394,000 reported for the same period last year. , ... compared to a net profit for the same period of the prior fiscal year ...
... , , , LEXINGTON, ... for Genome Resources (NCGR) has selected febit,s DNA-capture method, HybSelect(TM), ... of the most devastating childhood diseases with the ultimate goal ... genetic diseases in prospective parents. , , ...
... and VANCOUVER, Aug. 10 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, ... that the United States Patent and Trademark Office ... entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 ... cancer drug candidate, OGX-011, to treat certain cancers. ...
Cached Biology Technology:Imagenetix, Inc. Reports First Quarter 2010 Results 2Imagenetix, Inc. Reports First Quarter 2010 Results 3Imagenetix, Inc. Reports First Quarter 2010 Results 4Imagenetix, Inc. Reports First Quarter 2010 Results 5The National Center for Genome Resources Studies Childhood Diseases Using febit's DNA Capture Method 2The National Center for Genome Resources Studies Childhood Diseases Using febit's DNA Capture Method 3OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011 2OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011 3